{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:30:52Z","timestamp":1777941052248,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Foundation of Capital Distinctive Clinical Application Research","award":["Z181100001718131"],"award-info":[{"award-number":["Z181100001718131"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Technol Cancer Res Treat"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>Objective: We assessed the efficacy and safety of transarterial chemoembolization (TACE) in combination with lenvatinib plus programmed death receptor-1 (PD-1) signaling inhibitors (camrelizumab or sintilimab) in unresectable hepatocellular carcinoma (uHCC). Methods: In this retrospective study, patients with uHCC were pretreated with lenvatinib for 1 to 2 weeks before TACE. Camrelizumab or sintilimab were initially administered intravenously in 1 week after TACE of a 21-day cycle. Primary objectives were objective response rate (ORR) and disease control rate (DCR) by modified Response Evaluation Criteria in Solid Tumors (mRECIST). The secondary endpoints included the progression-free survival (PFS), overall survival (OS), and toxicity. Results: Between March 5, 2019 and February 30, 2021, 53 patients were screened for eligibility. At data cutoff, 35.8% of patients remained on treatment. Median follow-up was 15.4 months. Confirmed ORR in the 51 evaluable patients was 54.9% (95% CI 41.4%-67.7%). DCR was 84.3% (95% CI 72.0%-91.8%). Median PFS was 8.5 months (95% CI 6.4 to 10.6 months). The median OS was not estimable. Grade \u22653 treatment-related adverse events occurred in 32.1% of patients. No new safety signals were identified. Conclusion: TACE in combination with lenvatinib plus anti-PD-1 inhibitors may have promising antitumor activity in uHCC. Toxicities were manageable, with no unexpected safety signals.<\/jats:p>","DOI":"10.1177\/15330338221075174","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T03:09:17Z","timestamp":1647918557000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":35,"title":["A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients  With Unresectable Hepatocellular  Carcinoma"],"prefix":"10.1177","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1527-2856","authenticated-orcid":false,"given":"Ying","family":"Teng","sequence":"first","affiliation":[{"name":"Beijing Ditan Hosipital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Ding","sequence":"additional","affiliation":[{"name":"Beijing Ditan Hosipital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendong","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Ditan Hosipital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[{"name":"Beijing Ditan Hosipital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinglong","family":"Chen","sequence":"additional","affiliation":[{"name":"Beijing Ditan Hosipital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"key":"bibr1-15330338221075174","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"bibr2-15330338221075174","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"bibr3-15330338221075174","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30127-X"},{"key":"bibr4-15330338221075174","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50047"},{"key":"bibr5-15330338221075174","doi-asserted-by":"publisher","DOI":"10.1159\/000368142"},{"key":"bibr6-15330338221075174","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22655"},{"key":"bibr7-15330338221075174","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318934"},{"key":"bibr8-15330338221075174","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"bibr9-15330338221075174","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11758"},{"key":"bibr10-15330338221075174","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"bibr11-15330338221075174","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6"},{"key":"bibr12-15330338221075174","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.29"},{"key":"bibr13-15330338221075174","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212513"},{"key":"bibr14-15330338221075174","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.4suppl.513"},{"key":"bibr15-15330338221075174","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"bibr16-15330338221075174","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11644"},{"key":"bibr17-15330338221075174","doi-asserted-by":"publisher","DOI":"10.1177\/2050640616673516"},{"key":"bibr18-15330338221075174","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.578633"},{"key":"bibr19-15330338221075174","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2021.06.003"},{"key":"bibr20-15330338221075174","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081084"},{"key":"bibr21-15330338221075174","doi-asserted-by":"publisher","DOI":"10.1126\/science.1104819"},{"key":"bibr22-15330338221075174","doi-asserted-by":"publisher","DOI":"10.1159\/000502905"},{"key":"bibr23-15330338221075174","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12069"},{"key":"bibr24-15330338221075174","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13806"},{"key":"bibr25-15330338221075174","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00808"},{"key":"bibr26-15330338221075174","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.267"}],"container-title":["Technology in Cancer Research &amp; Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338221075174","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15330338221075174","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338221075174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:10:03Z","timestamp":1777702203000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15330338221075174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":26,"alternative-id":["10.1177\/15330338221075174"],"URL":"https:\/\/doi.org\/10.1177\/15330338221075174","relation":{},"ISSN":["1533-0346","1533-0338"],"issn-type":[{"value":"1533-0346","type":"print"},{"value":"1533-0338","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"15330338221075174"}}